FDA Approves Leqembi, Extending Alzheimer’s Treatment to More Patients
Medicare enrollees can get the anti-amyloid treatment as a result of the agency’s full approval. Source link
Neurodegenerative Disease Drugs
New Alzheimer’s Drug Leqembi Will Be Out of Reach for Most Patients
HealthMedicare won’t pay for medicine under rule issued to restrict use of earlier drug whose approval generated controversy Source link
Amylyx Prices Newly Approved ALS Drug at $12,500 a Month
The drug, called Relyvrio, was approved by the Food and Drug Administration late Thursday after some staff had raised questions...
Alzheimer’s Drug Slows Disease Progression in Trial
The pharmaceutical companies said their drug lecanemab reduced cognitive and functional decline by 27%, compared with a placebo, over 18...
Biogen Agrees to Pay $900 Million Over Alleged Improper Physician Payments
Biogen Inc. agreed to pay $900 million to settle allegations that it paid kickbacks to doctors to induce them to...
Americans With ALS Look to Canada for Promising Drug the U.S. Hasn’t Approved
Canada approved Amylyx Pharmaceuticals Inc.’s new drug for amyotrophic lateral sclerosis last week. Now some U.S. patients with the fatal...
FDA Rejects Short Sellers’ Request to Halt Trials of Alzheimer’s Drug
The Food and Drug Administration has denied a petition by short sellers to halt clinical trials of an experimental Alzheimer’s...
Biogen to Sell Biosimilar-Venture Stake to Partner Samsung Biologics
Biogen Inc. is selling its share in biosimilar joint venture Samsung Bioepis for at least $2.25 billion to partner Samsung...
